Understanding how ARID1A mutations affect gastric cancer in Latino populations
The role of ARID1A mutations in Latino gastric cancer biology and disparities
This study is looking at how changes in the ARID1A gene affect stomach cancer, especially in Latino patients, and it aims to create new models to better understand the disease and test current treatments to help improve care for diverse groups.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11064500 on NIH RePORTER |
What this research studies
This research focuses on the role of ARID1A gene mutations in the biology of gastric cancer, particularly within Latino populations. By establishing and characterizing new patient-derived xenografts (PDXs), the study aims to create preclinical models that reflect the diversity of cancer patients. These models will be used to explore the mechanisms of cancer development and to test existing FDA-approved therapies, ultimately aiming to improve treatment outcomes for underrepresented groups. The research involves collaboration among several leading cancer centers to ensure a comprehensive approach to cancer health disparities.
Who could benefit from this research
Good fit: Ideal candidates for this research are Latino individuals diagnosed with gastric cancer, particularly those with ARID1A mutations.
Not a fit: Patients who do not have gastric cancer or those outside the Latino demographic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for Latino patients with gastric cancer.
How similar studies have performed: Previous research has shown promise in using patient-derived xenografts to study cancer biology and test therapies, indicating a strong potential for success in this approach.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Carvajal Carmona, Luis Guillermo — University of California at Davis
- Study coordinator: Carvajal Carmona, Luis Guillermo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.